What Is Recent in Pancreatic Cancer Immunotherapy?
Joint Authors
Amedei, Amedeo
Prisco, Domenico
Niccolai, Elena
D'Elios, Mario M.
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-14, 14 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-12-26
Country of Publication
Egypt
No. of Pages
14
Main Subjects
Abstract EN
Pancreatic cancer (PC) represents an unresolved therapeutic challenge, due to the poor prognosis and the reduced response to currently available treatments.
Pancreatic cancer is the most lethal type of digestive cancers, with a median survival of 4–6 months.
Only a small proportion of PC patients is curative by surgical resection, whilst standard chemotherapy for patients in advanced disease generates only modest effects with considerable toxic damages.
Thus, new therapeutic approaches, specially specific treatments such as immunotherapy, are needed.
In this paper we analyze recent preclinical and clinical efforts towards immunotherapy of pancreatic cancer, including passive and active immunotherapy approaches, designed to target pancreatic-cancer-associated antigens and to elicit an antitumor response in vivo.
American Psychological Association (APA)
Niccolai, Elena& Prisco, Domenico& D'Elios, Mario M.& Amedei, Amedeo. 2012. What Is Recent in Pancreatic Cancer Immunotherapy?. BioMed Research International،Vol. 2013, no. 2013, pp.1-14.
https://search.emarefa.net/detail/BIM-1004444
Modern Language Association (MLA)
Niccolai, Elena…[et al.]. What Is Recent in Pancreatic Cancer Immunotherapy?. BioMed Research International No. 2013 (2013), pp.1-14.
https://search.emarefa.net/detail/BIM-1004444
American Medical Association (AMA)
Niccolai, Elena& Prisco, Domenico& D'Elios, Mario M.& Amedei, Amedeo. What Is Recent in Pancreatic Cancer Immunotherapy?. BioMed Research International. 2012. Vol. 2013, no. 2013, pp.1-14.
https://search.emarefa.net/detail/BIM-1004444
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1004444